Regional chemotherapy in the treatment of advanced pancreatic cancer — is it relevant?

• Published in: European Journal of Cancer 2000-05, Vol.36 (8), p.957-965
• Main Authors: Lorenz, M., Heinrich, S., Staib-Sebler, E., Köhne, C.-H., Wils, J., Nordlinger, B., Encke, A.
• Format: Article
• Language: English
• Subjects: Antineoplastic Agents - administration & dosage; Aortic stop flow; Celiac axis infusion; Chemotherapy, Cancer, Regional Perfusion; Humans; Isolated hypoxic perfusion; Pancreatic cancer; Pancreatic Neoplasms - drug therapy; Regional chemotherapy; Treatment Outcome
• ISSN: 0959-8049; 1879-0852
• DOI: 10.1016/S0959-8049(00)00073-3

The treatment of pancreatic cancer is still problematic for physicians. Only 15% of patients present with resectable tumours, and systemic chemotherapy is of limited effectiveness. In order to achieve higher local drug concentrations in the tumour without causing the side-effects of a comparable level of systemic treatment, regional chemotherapy has been introduced as an alternative treatment. Several techniques have been developed over recent years, these include: celiac axis infusion (CAI), CAI with microspheres or haemofiltration, aortic stop flow (ASF) and isolated hypoxic perfusion (IHP). Whilst several authors have reported improved response rates and a prolongation of median survival time, these results have not been confirmed by others. In addition, the incidence of side-effects and the rate of technical complications have been reported to be high during regional chemotherapy. Except for a single trial containing 14 patients, no randomised trial comparing systemic and regional chemotherapy has been conducted. For these reasons, none of the reported treatment regimens can be considered to be standard treatment and in order to evaluate, if regional chemotherapy is indeed superior to systemic chemotherapy, randomised trials must be conducted.